PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) fell 8.1% during trading on Wednesday . The stock traded as low as $0.6699 and last traded at $0.6949. 183,632 shares traded hands during trading, an increase of 1,979% from the average session volume of 8,831 shares. The stock had previously closed at $0.7558.
PharmaCyte Biotech Stock Up 2.8%
The firm has a fifty day simple moving average of $0.71 and a 200-day simple moving average of $0.79.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
Featured Stories
- Five stocks we like better than PharmaCyte Biotech
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
